NFKB1 and metabolic dysfunction-associated steatohepatitis: Gemcabene 100 and 300 mg/kg down-regulated NF-kB mRNA expression levels (0.9 ± 0.1 and 0.8 ± 0.1, respectively) compared to the vehicle-treated NASH mice.